The BCL2L10 Leu21Arg variant and risk of therapy-related myeloid neoplasms and de novo myelodysplastic syndromes

References

• Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009;114: 937–951
   PubMed Web of Science ®Google Scholar
• Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature 2001;411:366–374.
   PubMed Web of Science ®Google Scholar
• Ljungman M, Lane DP. Transcription - guarding the genome by sensing DNA damage. Nat Rev Cancer 2004;4:727–737.
   PubMed Web of Science ®Google Scholar
• Knight JA, Skol AD, Shinde A, et al. Genome-wide association study to identify novel loci associated with therapy-related myeloid leukemia susceptibility. Blood 2009;113:5575–5582.
   PubMed Web of Science ®Google Scholar
• Schulz E, Valentin A, Ulz P, et al. Germline mutations in the DNA damage response genes BRCA1, BRCA2, BARD1 and TP53 in patients with therapy related myeloid neoplasms. J Med Genet 2012;49: 422–428.
   PubMed Web of Science ®Google Scholar
• Felix CA, Walker AH, Lange BJ, et al. Association of CYP3A4 genotype with treatment-related leukemia. Proc Natl Acad Sci USA 1998;95:13176–13181.
   PubMed Web of Science ®Google Scholar
• Kelly KM, Perentesis JP. Polymorphisms of drug metabolizing enzymes and markers of genotoxicity to identify patients with Hodgkin's lymphoma at risk of treatment-related complications. Ann Oncol 2002;13(Suppl. 1):34–39.
   PubMed Web of Science ®Google Scholar
• Worrillow LJ, Allan JM. Deregulation of homologous recombination DNA repair in alkylating agent-treated stem cell clones: a possible role in the aetiology of chemotherapy-induced leukaemia. Oncogene 2006;25:1709–1720.
   PubMed Web of Science ®Google Scholar
• Voso MT, Hohaus S, Guidi F, et al. Prognostic role of glutathione S-transferase polymorphisms in acute myeloid leukemia. Leukemia 2008;22:1685–1691.
   PubMed Web of Science ®Google Scholar
• Fabiani E, Leone G, Giachelia M, et al. Analysis of genome-wide methylation and gene expression induced by 5-aza-20-deoxycytidine identifies BCL2L10 as a frequent methylation target in acute myeloid leukemia. Leuk Lymphoma 2010;51:2275–2284.
   PubMed Web of Science ®Google Scholar
• Fabiani E, D’Alò F, Scardocci A, et al. Polymorphisms of detoxification and DNA repair enzymes in myelodyplastic syndromes. Leuk Res 2009;3:1068–1071.
   Web of Science ®Google Scholar
• Voso MT, Fabiani E, D’Alò F, et al. Increased risk of acute myeloid leukemia due to polymorphisms in detoxification and DNA repair enzymes. Ann Oncol 2007;18:1523–1528.
   PubMed Web of Science ®Google Scholar
• Allan JM, Wild CP, Rollinson S, et al. Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia. Proc Natl Acad Sci USA 2001;98:11592–11597.
   PubMed Web of Science ®Google Scholar
• Mikata R, Fukai K, Imazeki F, et al.BCL2L10 is frequently silenced by promoter hypermethylation in gastric cancer. Oncol Rep 2010;23:1701–1708.
   PubMed Web of Science ®Google Scholar
• Xu JD, Cao XX, Long ZW, et al. BCL2L10 protein regulates apoptosis/proliferation through differential pathways in gastric cancer cells. J Pathol 2011;223:400–409.
   PubMed Web of Science ®Google Scholar
• Naoe T, Takeyama K, Yokozawa T, et al. Analysis of genetic polymorphism in NQO1, GST-M1, GST-T1, and CYP3A4 in 469 Japanese patients with therapy-related leukemia/myelodysplastic syndrome and de novo acute myeloid leukemia. Clin Cancer Res 2000;6:4091–4095.
   PubMed Web of Science ®Google Scholar
• Seedhouse C, Bainton R, Lewis M, et al. The genotype distribution of the XRCC1 gene indicates a role for base excision repair in the development of therapy-related acute myeloblastic leukemia. Blood 2002;100:3761–3766.
   PubMed Web of Science ®Google Scholar
• Seedhouse C, Faulkner R, Ashraf N, et al. Polymorphisms in genes involved in homologous recombination repair interact to increase the risk of developing acute myeloid leukemia. Clin Cancer Res 2004;10:2675–2680.
   PubMed Web of Science ®Google Scholar
• Zimniak P, Nanduri B, Pikuła S, et al. Naturally occurring human glutathione S-transferase GSTP1-1 isoforms with isoleucine and valine in position 104 differ in enzymatic properties. Eur J Biochem 1994;224:893–899.
   PubMedGoogle Scholar
• Voso MT, Fabiani E, Piciocchi A, et al. Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-azacytidine. Leukemia 2011;25:1910–1913.
   PubMed Web of Science ®Google Scholar
• Cluzeau T, Robert G, Mounier N, et al. BCL2L10 is a predictive factor for resistance to azacitidine in MDS and AML patients. Oncotarget 2012;3:490–501.
   PubMedGoogle Scholar
• Mikata R, Yokosuka O, Fukai K, et al. Analysis of genes upregulated by the demethylating agent 5-aza-2-deoxycytidine in gastric cancer cell lines. Int J Cancer 2006;119:1616–1622.
   PubMed Web of Science ®Google Scholar
• Inohara N, Gourley TS, Carrio R, et al. Diva, a Bcl-2 homologue that binds directly to Apaf-1 and induces BH3-independent cell death. J Biol Chem 1998;273:32479–32486.
   PubMed Web of Science ®Google Scholar
• Ke N, Godzik A, Reed JC. Bcl-B, a novel Bcl-2 family member that differentially binds and regulates Bax and Bak. J Biol Chem 2001;20:12481–12484.
   Web of Science ®Google Scholar
• Luciano F, Krajewska M, Ortiz-Rubio P, et al. Nur77 converts phenotype of Bcl-B, an antiapoptotic protein expressed in plasma cells and myeloma. Blood 2007;109:3849–3855.
   PubMed Web of Science ®Google Scholar
• Beverly LJ, Lockwood WW, Shah PP, et al. Ubiquitination, localization, and stability of an anti-apoptotic BCL2-like protein, BCL2L10/BCLb, are regulated by Ubiquilin1. Proc Natl Acad Sci USA 2012;109:119–126.
   PubMed Web of Science ®Google Scholar
• Krajewska M, Kitada S, Winter JN, et al. Bcl-B expression in human epithelial and nonepithelial malignancies. Clin Cancer Res 2008;14:3011–3021.
   Google Scholar
• Beverly LJ, Varmus H. MYC-induced myeloid leukemogenesis is accelerated by all six members of the antiapoptotic BCL family. Oncogene 2009;28:1274–1279.
   PubMed Web of Science ®Google Scholar
• Guillemin Y, Cornut-Thibaut A, Gillet G, et al. Characterization of unique signature sequences in the divergent maternal protein Bcl2l10. Mol Biol Evol 2011;28:3271–3283.
   PubMed Web of Science ®Google Scholar
• Fianchi L, Criscuolo M, Lunghi M, et al. Outcome of therapy-related myeloid neoplasms treated with azacitidine. J Hematol Oncol 2012;5:44.
   PubMed Web of Science ®Google Scholar